Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

The Pediatric infectious disease journal - 1 May 2003

Karron Ruth A, Belshe Robert B, Wright Peter F, Thumar Bhagvanji, Burns Barbars, Newman Frances, Cannon Joan C, Thompson Juliette, Tsai Theodore, Paschalis Maribel, Wu Shin-Lu, Mitcho Yvonne, Hackell Jill, Murphy Brian R, Tatem Joanna M

Abstract excerpt

BACKGROUND: Parainfluenza type 3 virus (PIV-3) infections cause lower respiratory tract illness in children throughout the world. A licensed PIV-3 vaccine is not yet available. METHODS: A live attenuated cold-adapted (ca) and temperature-sensitive (ts) PIV-3 vaccine, designated cp-45, was evaluated sequentially in open label studies in 20 adults and in placebo-controlled, double blind studies in 24...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunity

Share to Probability

Share to Reference Values

Share to Vaccination

Share to Vaccines, Attenuated

Share to Viral Vaccines

Source

Identifiers

PMID: 12792378
DOI: 10.1097/01.inf.0000066244.31769.83

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.PMID 12792378Read ↗

A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.Semantic proximity Read ↗

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.Semantic proximity Read ↗

Current status of vaccines for parainfluenza virus infections.Semantic proximity Read ↗

A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.Semantic proximity Read ↗

Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.Semantic proximity Read ↗

PIV-3 vaccine National Institutes of Health/Aviron.Semantic proximity Read ↗

Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.Semantic proximity Read ↗

Immunology of viral respiratory tract infection in infancy.Semantic proximity Read ↗

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.Semantic proximity Read ↗

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.Semantic proximity Read ↗

Challenges in developing a pediatric RSV vaccineSemantic proximity Read ↗

Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.